Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIAM: carboplatin + paclitaxel + pembrolizumab for locoregionally advanced penile cancer
2023-506731-15-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel and carboplatin in penile squamous cell carcinoma (PSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Pathological complete response in intention-to-treat population. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2023-506731-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506731-15-00.